Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation for Treatment of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF \<40% using nuclear ventriculography or echocardiography within the last 6 months.~* Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.~* Patients with a 25(OH)D level between 10-25 ng/ml~Exclusion Criteria:~* Inability to give informed consent~* Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism~* Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF~* Renal dysfunction defined as serum creatinine \> 2.5 mg/dl~* Pregnant women~* Patients \<18 years of age~* Patients on vitamin D supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): A placebo loading dose will be given followed by two placebo tablets daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).